These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

741 related articles for article (PubMed ID: 30935847)

  • 1. Association between immune-related adverse events and prognosis in patients with metastatic renal cell carcinoma treated with nivolumab.
    Ishihara H; Takagi T; Kondo T; Homma C; Tachibana H; Fukuda H; Yoshida K; Iizuka J; Kobayashi H; Okumi M; Ishida H; Tanabe K
    Urol Oncol; 2019 Jun; 37(6):355.e21-355.e29. PubMed ID: 30935847
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic impact of immune-related adverse events in metastatic renal cell carcinoma treated with nivolumab plus ipilimumab.
    Ikeda T; Ishihara H; Nemoto Y; Tachibana H; Fukuda H; Yoshida K; Takagi T; Iizuka J; Hashimoto Y; Ishida H; Kondo T; Tanabe K
    Urol Oncol; 2021 Oct; 39(10):735.e9-735.e16. PubMed ID: 34172370
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real-world efficacy and safety of nivolumab in previously-treated metastatic renal cell carcinoma, and association between immune-related adverse events and survival: the Italian expanded access program.
    Verzoni E; Cartenì G; Cortesi E; Giannarelli D; De Giglio A; Sabbatini R; Buti S; Rossetti S; Cognetti F; Rastelli F; Sobrero A; Turci D; Sternberg CN; Porta C; Cappuzzo F; Tortora G; Tassinari D; Panni S; Pazzola A; Surico G; Raimondi A; De Giorgi U; Procopio G;
    J Immunother Cancer; 2019 Apr; 7(1):99. PubMed ID: 30944023
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Correlation between immune-related adverse events and prognosis in patients with gastric cancer treated with nivolumab.
    Masuda K; Shoji H; Nagashima K; Yamamoto S; Ishikawa M; Imazeki H; Aoki M; Miyamoto T; Hirano H; Honma Y; Iwasa S; Okita N; Takashima A; Kato K; Boku N
    BMC Cancer; 2019 Oct; 19(1):974. PubMed ID: 31638948
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Correlation Between Immune-related Adverse Event (IRAE) Occurrence and Clinical Outcome in Patients With Metastatic Renal Cell Carcinoma (mRCC) Treated With Nivolumab: IRAENE Trial, an Italian Multi-institutional Retrospective Study.
    Vitale MG; Pipitone S; Venturelli M; Baldessari C; Porta C; Iannuzzi F; Basso U; Scagliarini S; Zucali PA; Galli L; Rossetti S; Caserta C; Bracarda S; Iacovelli R; Masini C; Cortellini A; Di Girolamo S; Buti S; Fornarini G; Carrozza F; Santoni M; Caputo F; Giaquinta S; Balduzzi S; D'Amico R; Vitale G; Mighali P; Sabbatini R
    Clin Genitourin Cancer; 2020 Dec; 18(6):477-488. PubMed ID: 32732112
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immune-Related Adverse Events as Clinical Biomarkers in Patients with Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors.
    Martini DJ; Goyal S; Liu Y; Evans ST; Olsen TA; Case K; Magod BL; Brown JT; Yantorni L; Russler GA; Caulfield S; Goldman JM; Nazha B; Harris WB; Kissick HT; Master VA; Kucuk O; Carthon BC; Bilen MA
    Oncologist; 2021 Oct; 26(10):e1742-e1750. PubMed ID: 34156726
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immune-related adverse events predict the therapeutic efficacy of anti-PD-1 antibodies in cancer patients.
    Rogado J; Sánchez-Torres JM; Romero-Laorden N; Ballesteros AI; Pacheco-Barcia V; Ramos-Leví A; Arranz R; Lorenzo A; Gullón P; Donnay O; Adrados M; Costas P; Aspa J; Alfranca A; Mondéjar R; Colomer R
    Eur J Cancer; 2019 Mar; 109():21-27. PubMed ID: 30682533
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association between immune-related adverse events and survival in patients with renal cell carcinoma treated with nivolumab plus ipilimumab: immortal time bias-corrected analysis.
    Washino S; Shirotake S; Takeshita H; Inoue M; Miura Y; Hyodo Y; Kagawa M; Izumi K; Oyama M; Kawakami S; Saito K; Matsuoka Y; Taniuchi S; Shintani A; Miyagawa T
    Int J Clin Oncol; 2023 Dec; 28(12):1651-1658. PubMed ID: 37658926
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and Efficacy of Nivolumab in Patients With Metastatic Renal Cell Carcinoma and End-stage Renal Disease at 2 Centers.
    Tachibana H; Kondo T; Ishihara H; Takagi T; Tanabe K
    Clin Genitourin Cancer; 2019 Aug; 17(4):e772-e778. PubMed ID: 31101580
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparable efficacy and safety between second-line and later-line nivolumab therapy for metastatic renal cell carcinoma.
    Ishihara H; Takagi T; Kondo T; Fukuda H; Tachibana H; Yoshida K; Iizuka J; Kobayashi H; Okumi M; Ishida H; Tanabe K
    Int J Clin Oncol; 2020 Apr; 25(4):705-712. PubMed ID: 31858306
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association Between Immune-related Adverse Events and Clinical Outcome Following Nivolumab Treatment in Patients With Metastatic Renal Cell Carcinoma.
    Kobayashi K; Iikura Y; Hiraide M; Yokokawa T; Aoyama T; Shikibu S; Hashimoto K; Suzuki K; Sato H; Sugiyama E; Tajima M; Hama T
    In Vivo; 2020; 34(5):2647-2652. PubMed ID: 32871795
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Correlation between immune-related adverse events and efficacy in non-small cell lung cancer treated with nivolumab.
    Sato K; Akamatsu H; Murakami E; Sasaki S; Kanai K; Hayata A; Tokudome N; Akamatsu K; Koh Y; Ueda H; Nakanishi M; Yamamoto N
    Lung Cancer; 2018 Jan; 115():71-74. PubMed ID: 29290265
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of immune-related adverse events on survival in patients with advanced non-small cell lung cancer treated with nivolumab: long-term outcomes from a multi-institutional analysis.
    Ricciuti B; Genova C; De Giglio A; Bassanelli M; Dal Bello MG; Metro G; Brambilla M; Baglivo S; Grossi F; Chiari R
    J Cancer Res Clin Oncol; 2019 Feb; 145(2):479-485. PubMed ID: 30506406
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of immune checkpoint inhibitors in elderly patients with metastatic renal cell carcinoma.
    Nemoto Y; Ishihara H; Nakamura K; Tachibana H; Fukuda H; Yoshida K; Kobayashi H; Iizuka J; Shimmura H; Hashimoto Y; Tanabe K; Kondo T; Takagi T
    Int Urol Nephrol; 2022 Jan; 54(1):47-54. PubMed ID: 34704214
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Correlation between immune-related adverse events and therapeutic effects of nivolumab in patients with malignant pleural mesothelioma.
    Yoneda H; Nokihara H; Mitsuhashi A; Ozaki R; Yabuki Y; Ogino H; Otsuka K; Nishioka Y
    BMC Pulm Med; 2021 Nov; 21(1):373. PubMed ID: 34781910
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Elevated eosinophils proportion as predictor of immune-related adverse events after ipilimumab and nivolumab treatment of advanced and metastatic renal cell carcinoma.
    Tasaki Y; Hamamoto S; Sugiyama Y; Tomiyama N; Naiki T; Etani T; Taguchi K; Matsuyama N; Sue Y; Mimura Y; Kubota H; Noda Y; Aoki M; Moritoki Y; Nozaki S; Kurokawa S; Okada A; Kawai N; Yasui T; Kimura K
    Int J Urol; 2023 Oct; 30(10):866-874. PubMed ID: 37278575
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Profiling Preexisting Antibodies in Patients Treated With Anti-PD-1 Therapy for Advanced Non-Small Cell Lung Cancer.
    Toi Y; Sugawara S; Sugisaka J; Ono H; Kawashima Y; Aiba T; Kawana S; Saito R; Aso M; Tsurumi K; Suzuki K; Shimizu H; Domeki Y; Terayama K; Nakamura A; Yamanda S; Kimura Y; Honda Y
    JAMA Oncol; 2019 Mar; 5(3):376-383. PubMed ID: 30589930
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identifying Early Predictive Markers for Immune-Related Adverse Events in Nivolumab-Treated Patients with Renal Cell Carcinoma and Gastric Cancer.
    Takada S; Murooka H; Tahatsu K; Yanase M; Umehara K; Hashishita H; Toru H; Satoru M; Sagawa T; Fujikawa K; Sato H; Mino K
    Asian Pac J Cancer Prev; 2022 Feb; 23(2):695-701. PubMed ID: 35225483
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Outcomes associated with immune-related adverse events in metastatic non-small cell lung cancer treated with nivolumab: a pooled exploratory analysis from a global cohort.
    Naqash AR; Ricciuti B; Owen DH; Florou V; Toi Y; Cherry C; Hafiz M; De Giglio A; Muzaffar M; Patel SH; Sugawara S; Burkart J; Park W; Chiari R; Sugisaka J; Otterson GA; de Lima Lopes G; Walker PR
    Cancer Immunol Immunother; 2020 Jul; 69(7):1177-1187. PubMed ID: 32140762
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic Impact of Immune-Related Adverse Events as First-Line Therapy for Metastatic Renal Cell Carcinoma Treated With Nivolumab Plus Ipilimumab: A Multicenter Retrospective Study.
    Nukaya T; Takahara K; Yoshizawa A; Saruta M; Yano Y; Ohno T; Uchimoto T; Fukuokaya W; Adachi T; Yamazaki S; Tokushige S; Nishimura K; Tsujino T; Nakamori K; Yamamoto S; Iwatani K; Urabe F; Mori K; Yanagisawa T; Tsuduki S; Hirasawa Y; Hashimoto T; Komura K; Inamoto T; Miki J; Kimura T; Ohno Y; Azuma H; Shiroki R
    Clin Genitourin Cancer; 2024 Feb; 22(1):76-83. PubMed ID: 37880020
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 38.